Can’t sign in? Forgot your password?
Enter your email address below and we will send you the reset instructions
If the address matches an existing account you will receive an email with instructions to reset your password.
Can’t sign in? Forgot your username?
Enter your email address below and we will send you your username
If the address matches an existing account you will receive an email with instructions to retrieve your username
Your password has been changed
Your Phone has been verified
Department of Cardiac Sciences, Libin Cardiovascular Institute, and Department of Community Health Sciences, O’Brien Institute for Public Health, University of Calgary, Alberta, Canada, and Duke Clinical Research Institute, Duke University, Durham, North Carolina (D.S.C.)
Search for more papers by this author
Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada (S.W.)
Search for more papers by this author
Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts (M.V.)
Search for more papers by this author
Duke Clinical Research Institute, Duke University, Durham, North Carolina (D.B.M.)
Search for more papers by this author
Department of Health Research Methods, Evidence and Impact and Department of Medicine, McMaster University, Population Health Research Institute, and Research Institute of St. Joseph’s, Hamilton, Ontario, Canada (H.G.C.V.S.).
Search for more papers by this author
Patient-reported outcomes (PROs) are important measures of treatment effect and can be used to inform the approval of cardiovascular drugs and devices by the U.S. Food and Drug Administration (FDA).
To catalogue the health status patient-reported outcome measures (PROMs) validated in cardiovascular diseases (CVDs), describe their psychometric properties, and assess adherence with both FDA recommendations and the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) framework.
MEDLINE, EMBASE, CINAHL, and Allied and Complementary Medicine Database from inception to August 2022.
Studies that developed and/or validated health status PROMs in CVD populations.
Two study authors extracted data on CVD type, PROM psychometric properties, and adherence to FDArecommendations. The risk of bias informing the development or validation of PROMs was assessed using the COSMIN framework.
Fifty health status PROMs (described in 83 studies) were identified, of which 45 were disease specific and 5 were generic. Eleven (22%) of the 50 PROMs validated in CVDs had minimally important differences (MIDs) established, and 8 (16%) reported on the validation of all psychometric properties recommended by the FDA. By COSMIN standards, only 2 PROMs (4%) had all of their psychometric properties rated as sufficient in quality, and 32 PROMs (64%) had less than 50% of psychometric properties rated as sufficient.
The quality of reporting varied across included studies.
Of 50 PROMs validated in CVDs, only a small minority reported on the validation of all FDA-recommended psychometric properties, had psychometric properties rated as sufficient by COSMIN, or had MIDs established. Given the use of PROMs to guide FDA approvals of drugs and devices in CVDs, there is a need for better adherence to quality standards in PROM validation.
None.
Department of Cardiac Sciences, Libin Cardiovascular Institute, and Department of Community Health Sciences, O’Brien Institute for Public Health, University of Calgary, Alberta, Canada, and Duke Clinical Research Institute, Duke University, Durham, North Carolina (D.S.C.)
Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada (S.W.)
Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts (M.V.)
Duke Clinical Research Institute, Duke University, Durham, North Carolina (D.B.M.)
Department of Health Research Methods, Evidence and Impact and Department of Medicine, McMaster University, Population Health Research Institute, and Research Institute of St. Joseph’s, Hamilton, Ontario, Canada (H.G.C.V.S.).
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M22-2234.
Reproducible Research Statement: Study protocol: Available from Dr. Van Spall (e-mail, Harriette.
Corresponding Author: Harriette G.C. Van Spall, MD, MPH, 20 Copeland Avenue, David Braley Research Building, Suite C3-117, Hamilton, ON L8L 0A3, Canada; e-mail, Harriette.
Author Contributions: Conception and design: D.S. Chew, H.G.C. Van Spall.
Analysis and interpretation of the data: D.S. Chew, D.B. Mark, H.G.C. Van Spall, S. Whitelaw.
Drafting of the article: D.S. Chew, H.G.C. Van Spall, S. Whitelaw.
Critical revision of the article for important intellectual content: D.S. Chew, D.B. Mark, M. Vaduganathan, H.G.C. Van Spall.
Final approval of the article: D.S. Chew, D.B. Mark, M. Vaduganathan, H.G.C. Van Spall, S. Whitelaw.
Provision of study materials or patients: H.G.C. Van Spall.
Statistical expertise: H.G.C. Van Spall.
Obtaining of funding: H.G.C. Van Spall.
Administrative, technical, or logistic support: H.G.C. Van Spall.
Collection and assembly of data: D.S. Chew, S. Whitelaw.
This article was published at Annals.org on 20 September 2022.
*Dr. Chew and Ms. Whitelaw contributed equally to this work.
Copyright © 2022 by American College of Physicians. All Rights Reserved.
Loading …
- Issue in Progress
- Archive
- CME / MOC
- Authors / Submit
- About
- Masthead
- About the Editors
- Reviewers
- Alerts
- Contact Us
- Help